Table 1.
Patients’ characteristics.
| Sex | ||
|---|---|---|
| Female | 144 | 39.3% |
| Male | 222 | 60.7% |
| Age, (IQR), [range] | 68 (58-77) [25–96] | |
| 18-25 years old | 2 | 0.5% |
| 26-50 years old | 36 | 9.8% |
| 51-69 years old | 154 | 42.1% |
| ≥ 70 years old | 174 | 47.5% |
| Comorbidities before COVID-19 | ||
| No comorbidities | 121 | 33.1% |
| 1 comorbidity | 113 | 30.9% |
| 2 comorbidities | 90 | 24.6% |
| 3 or more comorbidities | 42 | 11.5% |
| Chronic cardiopathy | 125 | 34.2% |
| Chronic pulmonary disease | 80 | 21.9% |
| Diabetes | 64 | 17.5% |
| Liver disease | 16 | 4.4% |
| Renal impairment | 26 | 7.1% |
| Obesity | 23 | 6.3% |
| Smoking history | 43 | 11.7% |
| No risk factor identified | 116 | 31.7% |
| Malignancy | ||
| Chronic lymphoid leukemia | 204 | 55.7% |
| Non-Hodgkin lymphoma | 162 | 44.3% |
| Malignancy status at COVID-19 diagnosis | ||
| Controlled malignancy | 213 | 58.2% |
| Complete remission | 92 | 25.1% |
| Partial remission | 121 | 33.1% |
| Stable malignancy | 59 | 16.1% |
| Active malignancy | 84 | 23.0% |
| Onset | 15 | 4.1% |
| Refractory/Resistant | 69 | 18.9% |
| Unknown | 10 | 2.7% |
| Time last chemotherapy before COVID-19 | ||
| In the last month | 255 | 69.7% |
| In the last 3 months | 52 | 14.2% |
| Chemotherapy ended > 3 months before COVID-19 | 57 | 15.6% |
| # lines until COVID-19 onset | ||
| 1 line | 128 | 35.0% |
| 2 lines | 109 | 29.8% |
| 3 lines | 69 | 18.9% |
| 4 lines | 30 | 8.2% |
| >4 lines | 30 | 8.2% |
| Neutrophils at COVID-19 onset | ||
| ≤ 500 | 15 | 4.1% |
| 501 - 999 | 17 | 4.6% |
| ≥ 1000 | 285 | 77.9% |
| Lymphocytes at COVID-19 onset | ||
| ≤ 200 | 22 | 6.0% |
| 201 - 499 | 43 | 11.7% |
| ≥ 500 | 249 | 68.0% |
| Last vaccination before COVID-19 | ||
| Not vaccinated | 288 | 78.7% |
| One dose | 19 | 5.2% |
| Two doses | 54 | 14.8% |
| Three doses | 5 | 1.4% |
| Last type of vaccination before COVID-19 | ||
| mRNA | 65 | 17.8% |
| BioNTech/Pfizer | 53 | 14.5% |
| Moderna COVE | 12 | 3.3% |
| Vector-based | 11 | 3.0% |
| AstraZeneca Oxford | 9 | 2.5% |
| Sputnik | 1 | 0.3% |
| J&J - Janssen | 1 | 0.3% |
| Inactivated | 2 | 0.5% |
| CoronaVac | Sinovac | 2 | 0.5% |
| COVID-19 severity | ||
| Asymptomatic | 59 | 16.1% |
| Mild infection | 53 | 14.5% |
| Severe infection | 174 | 47.5% |
| Critical infection | 80 | 21.9% |
| COVID-19 symptoms at onset | ||
| Pulmonary | 135 | 36.9% |
| Pulmonary + Extrapulmonary | 107 | 29.2% |
| Extrapulmonary | 62 | 16.9% |
| Screening | 62 | 16.9% |
| Stay during COVID-19 episode | ||
| Home | 106 | 29.0% |
| Hospital | 277 | 75.7% |
| ICU | 80 | 21.9% |
| Invasive mechanical ventilation | 55 | 15.0% |
| Non-invasive mechanical ventilation | 29 | 7.9% |
| Outcome | ||
| Mortality | 134 | 36.6% |
| COVID-19 | 92 | 25.1% |
| COVID-19 + Hematological malignancies | 28 | 7.7% |
| Hematological malignancies ± other reason(s) | 14 | 3.8% |